A genetic model for gallbladder carcinogenesis and its dissemination

Annals of Oncology

Volumn 25, Issue 6, 2014, Pages 1086-1097

  Barreto, S G ^a   Dutt, Amit ^b   Chaudhary, A ^a  

^a Medanta Institute of Digestive and Hepatobiliary Sciences   (India)

^b TATA MEMORIAL HOSPITAL   (India)

Author keywords

Biology; Carcinogenesis; Dissemination; Gallbladder cancer; Genetic alteration; Therapeutics

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLOOXYGENASE 2; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MUCIN; PROTEIN P16; TUMOR MARKER;

CANCER MODEL; CANCER PATIENT; CANCER RISK; CANCER SURGERY; CARCINOGENESIS; CHROMOSOME DELETION; CHROMOSOME DELETION 18Q21; COLORECTAL CANCER; EVIDENCE BASED PRACTICE; EVOLUTION; FRAGILE HISTIDINE TRIAD GENE; GALLBLADDER CANCER; GALLBLADDER CARCINOMA; GASTROINTESTINAL DYSPLASIA; GENE; GENETIC MODEL; GENETIC RISK; HETEROZYGOSITY LOSS; HUMAN; INFLAMMATION; METASTASIS; MICROSATELLITE INSTABILITY; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR SUPPRESSOR GENE; BIOLOGICAL MODEL; GALLBLADDER TUMOR; GENETICS; TUMOR INVASION;

CARCINOGENESIS; GALLBLADDER NEOPLASMS; HUMANS; MODELS, GENETIC; NEOPLASM INVASIVENESS;

EID: 84903881283     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu006     Document Type: Review

References (127)

1. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. Alexander S, Lemmens VE, Houterman S et al. Gallbladder cancer, a vanishing disease? Cancer Causes Control 2012; 23: 1705-1709.
3. Le MD, Henson D, Young H et al. Is gallbladder cancer decreasing in view of increasing laparoscopic cholecystectomy? Ann Hepatol 2011; 10: 306-314.
4. Dhir V, Mohandas KM. Epidemiology of digestive tract cancers in India IV. Gall bladder and pancreas. Indian J Gastroenterol 1999; 18: 24-28.
5. Shrikhande S, Barreto S, Singh S et al. Cholelithiasis in gallbladder cancer: coincidence, cofactor, or cause! Eur J Surg Oncol 2010; 36: 514-519.
6. Curado M, Edwards B, Shin H et al. Cancer Incidence in Five Continents. IARC Scientific Publications, 2007; IX.
7. Shukla PJ, Neve R, Barreto SG et al. A new scoring system for gallbladder cancer (aiding treatment algorithm): an analysis of 335 patients. Ann Surg Oncol 2008; 15: 3132-3137.
8. Doval D, Sekhon J, Gupta S et al. A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gallbladder cancer. Br J Cancer 2004; 90: 1516-1520.
9. Boutros C, Gary M, Baldwin K et al. Gallbladder cancer: past, present and an uncertain future. Surg Oncol 2012; 21: e183-191.
10. Shrikhande SV, Barreto SG. Surgery for gallbladder cancer: the need to generate greater evidence. World J Gastrointest Surg 2009; 1: 26-29.
11. Fearon E, Voglestein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767.
12. Laitio M. Early carcinoma of the gallbladder. Beitr Pathol 1976; 158: 159-172.
13. Laitio M. Histogenesis of epithelial neoplasms of human gallbladder I. Dysplasia. Pathol Res Pract 1983; 178: 51-56.
14. Albores-Saavedra J, Alcántra-Vazquez A, Cruz-Ortiz H et al. The precursor lesions of invasive gallbladder carcinoma. Hyperplasia, atypical hyperplasia and carcinoma in situ. Cancer 1980; 45: 919-927.
15. Roa I, Araya J, Villaseca M et al. Preneoplastic lesions and gallbladder cancer: an estimate of the period required for progression. Gastroenterology 1996; 111: 232-236.
16. Roa I, Aretxabala XD, Roa J et al. Preneoplastic lesions in gallbladder cancer. J Surg Oncol 2006; 93: 615-623.
17. Yamagiwa H, Tomiyama H. Intestinal metaplasia-dysplasia-carcinoma sequence of the gallbladder. Acta Pathol Jpn 1986; 36: 989-997.
18. Duarte I, Llanos O, Domke H et al. Metaplasia and precursor lesions of gallbladder carcinoma. Frequency, distribution, and probability of detection in routine histologic samples. Cancer 1993; 72: 1878-1884.
19. Roa I, Araya J, Wistuba I et al. Epithelial lesions associated with gallbladder carcinoma. A methodical study of 32 cases. Rev Med Chil 1993; 121: 21-29.
20. Wistuba I, Gazdar A, Roa I et al. p53 protein overexpression in gallbladder carcinoma and its precursor lesions: an immunohistochemical study. Hum Pathol 1996; 27: 360-365.
21. Misra S, Chaturvedi A, Goel M et al. Overexpression of p53 protein in gallbladder carcinoma in North India. Eur J Surg Oncol 2000; 26: 164-167.
22. Kozuka S, Tsubone N, Yasui A et al. Relation of adenoma to carcinoma in the gallbladder. Cancer 1982; 50: 2226-2234.
23. Watanabe H, Date K, Itoi T et al. Histological and genetic changes in malignant transformation of gallbladder adenoma. Ann Oncol 1999; 10; 136-139.
24. Nakajo S, Yamamoto M, Tahara E. Morphometrical analysis of gallbladder adenoma and adenocarcinoma with reference to histogenesis and adenoma- carcinoma sequence. Virchows Arch A Pathol Anat Histopathol 1990; 417: 49-56.
25. Sasatomi E, Tokunaga O, Miyazaki K. Precancerous conditions of gallbladder carcinoma: overview of histopathologic characteristics and molecular genetic findings. J Hepatobiliary Pancreat Surg 2000; 7: 556-567.
26. Goldin R, Roa J. Gallbladder cancer: a morphological and molecular update. Histopathology 2009; 55: 218-229.
27. Pai RK, Mojtahed K. Mutations in the RAS/RAF/MAP kinase pathway commonly occur in gallbladder adenomas but are uncommon in gallbladder adenocarcinomas. Appl Immunohistochem Mol Morphol 2011; 19: 133-140.
28. Shukla P, Barreto S, Gupta P et al. Is there a role for estrogen and progesterone receptors in gall bladder cancer? HPB (Oxford) 2007; 9: 285-288.
29. Shukla P, Barreto S, Shrikhande S et al. Simultaneous gallbladder and bile duct cancers: revisiting the pathological possibilities. HPB (Oxford) 2008; 10: 48-53.
30. Chijiiwa K, Tanaka M, Nakayama F. Adenocarcinoma of the gallbladder associated with anomalous pancreaticobiliary ductal junction. Am Surg 1993; 59: 430-434.
31. Wistuba II, Albores-Saavedra J. Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma. J Hepatobiliary Pancreat Surg 1999; 6: 237-244.
32. Wistuba II, Gazdar AF. Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer 2004; 4: 695-706.
33. Castillo J, Garcia P, Roa J. Genetic alterations in preneoplastic and neoplatic injuries of the gallbladder. Rev Med Chile 2010; 138: 596-604.
34. Tazuma S, Kajiyama G. Carcinogenesis of malignant lesions of the gall bladder. The impact of chronic inflammation and gallstones. Langenbecks Arch Surg 2001; 386: 224-229.
35. Tanno S, Obara T, Fujii T et al. Epithelial hyperplasia of the gallbladder in children with anomalous pancreaticobiliary ductal union. Hepatogastroenterology 1999; 46: 3068-3073.
36. Hanada K, Itoh M, Fujii K et al. Pathology and cellular kinetics of gallbladder with an anomalous junction of the pancreaticobiliary duct. Am J Gastroenterol 1996; 91: 1007-1011.
37. Hanada K, Tsuchida A, Kajiyama G. Cellular kinetics and gene mutations in gallbladder mucosa with an anomalous junction of pancreaticobiliary duct. J Hepatobiliary Pancreat Surg 1999; 6: 223-228.
38. Roa EI, Munoz NS, Ibacache SG et al. Natural history of gallbladder cancer. Analysis of biopsy specimens. Rev Med Chil 2009; 137: 873-880.
39. Roa JC, Roa I, Correa P et al. Microsatellite instability in preneoplastic and neoplastic lesions of the gallbladder. J Gastroenterol 2005; 40: 79-86.
40. Lin HT, Liu GJ, Wu D et al. Metastasis of primary gallbladder carcinoma in lymph node and liver. World J Gastroenterol 2005; 11: 748-751.
41. Albores-Saavedra J, Chable-Montero F, Gonzalez-Romo MA et al. Adenomas of the gallbladder. Morphologic features, expression of gastric and intestinal mucins, and incidence of high-grade dysplasia/carcinoma in situ and invasive carcinoma. Hum Pathol 2012; 43: 1506-1513.
42. Rai R, Tewari M, Kumar M et al. p53: its alteration and gallbladder cancer. Eur J Cancer Prev 2011; 20: 77-85.
43. Yokoyama N, Hitomi J, Watanabe H et al. Mutations of p53 in gallbladder carcinomas in high-incidence areas of Japan and Chile. Cancer Epidemiol Biomarkers Prev 1998; 7: 297-301.
44. Moreno M, Pimentel F, Gazdar AF et al. TP53 abnormalities are frequent and early events in the sequential pathogenesis of gallbladder carcinoma. Ann Hepatol 2005; 4: 192-199.
45. Wistuba II, Sugio K, Hung J et al. Allele-specific mutations involved in the pathogenesis of endemic gallbladder carcinoma in Chile. Cancer Res 1995; 55: 2511-2515.
46. Feng Z, Chen J, Wei H et al. The risk factor of gallbladder cancer: hyperplasia of mucous epithelium caused by gallstones associates with p16/CyclinD1/CDK4 pathway. Exp Mol Pathol 2011; 91: 569-577.
47. Kim YT, Kim J, Jang YH et al. Genetic alterations in gallbladder adenoma, dysplasia and carcinoma. Cancer Lett 2001; 169: 59-68.
48. Saetta A, Lazaris AC, Davaris PS. Detection of ras oncogene point mutations and simultaneous proliferative fraction estimation in gallbladder cancer. Pathol Res Pract 1996; 192: 532-540.
49. Hanada K, Tsuchida A, Iwao T et al. Gene mutations of K-ras in gallbladder mucosae and gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Am J Gastroenterol 1999; 94: 1638-1642.
50. Matsubara T, Sakurai Y, Sasayama Y et al. K-ras point mutations in cancerous and noncancerous biliary epithelium in patients with pancreaticobiliary maljunction. Cancer 1996; 77: 1752-1757.
51. Itoi T, Watanabe H, Ajioka Y et al. APC, K-ras codon 12 mutations and p53 gene expression in carcinoma and adenoma of the gall-bladder suggest two genetic pathways in gall-bladder carcinogenesis. Pathol Int 1996; 46: 333-340.
52. Legan M, Luzar B, Marolt VF et al. Expression of cyclooxygenase-2 is associated with p53 accumulation in premalignant and malignant gallbladder lesions. World J Gastroenterol 2006; 12: 3425-3429.
53. Fumino S, Tokiwa K, Ono S et al. Cyclooxygenase-2 expression in the gallbladder of patients with anomalous arrangement of the pancreaticobiliary duct. J Pediatr Surg 2003; 38: 585-589.
54. Ghosh M, Kawamoto T, Koike N et al. Cyclooxygenase expression in the gallbladder. Int J Mol Med 2000; 6: 527-532.
55. Yoshida T, Sugai T, Habano W et al. Microsatellite instability in gallbladder carcinoma: two independent genetic pathways of gallbladder carcinogenesis. J Gastroenterol 2000; 35: 768-774.
56. Rai R, Sharma KL, Tiwari S et al. DCC (deleted in colorectal carcinoma) gene variants confer increased susceptibility to gallbladder cancer (Ref. No.: Gene-D-12-01446). Gene 2013; 518: 303-309.
57. Cha PC, Zembutsu H, Takahashi A et al. A genome-wide association study identifies SNP in DCC is associated with gallbladder cancer in the Japanese population. J Hum Genet 2012; 57: 235-237.
58. Wistuba II, Ashfaq R, Maitra A et al. Fragile histidine triad gene abnormalities in the pathogenesis of gallbladder carcinoma. Am J Pathol 2002; 160: 2073-2079.
59. Koda M, Yashima K, Kawaguchi K et al. Expression of Fhit, Mlh1, and P53 protein in human gallbladder carcinoma. Cancer Lett 2003; 199: 131-138.
60. Knudson AG, Jr. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 1985; 45: 1437-1443.
61. Wistuba II, Maitra A, Carrasco R et al. High resolution chromosome 3p, 8p, 9q and 22q allelotyping analysis in the pathogenesis of gallbladder carcinoma. Br J Cancer 2002; 87: 432-440.
62. Chang HJ, Kim SW, Kim YT et al. Loss of heterozygosity in dysplasia and carcinoma of the gallbladder. Mod Pathol 1999; 12: 763-769.
63. Aarnio M, Sankila R, Pukkala E et al. Cancer risk in mutation carriers of DNAmismatch- repair genes. Int J Cancer 1999; 81: 214-218.
64. Kohya N, Miyazaki K, Matsukura S et al. Deficient expression of O(6)- methylguanine-DNA methyltransferase combined with mismatch-repair proteins hMLH1 and hMSH2 is related to poor prognosis in human biliary tract carcinoma. Ann Surg Oncol 2002; 9: 371-379.
65. Mishra PK, Raghuram GV, Jatawa SK et al. Frequency of genetic alterations observed in cell cycle regulatory proteins and microsatellite instability in gallbladder adenocarcinoma: a translational perspective. Asian Pac J Cancer Prev 2011; 12: 573-574.
66. Matsuda Y. Microsatellite instability meets gallbladder cancer. J Gastroenterol 2000; 35: 798-799.
67. Toledo C, Matus CE, Barraza X et al. Expression of HER2 and bradykinin B(1) receptors in precursor lesions of gallbladder carcinoma. World J Gastroenterol 2012; 18: 1208-1215.
68. Kamel D, Paakko P, Nuorva K et al. p53 and c-erbB-2 protein expression in adenocarcinomas and epithelial dysplasias of the gall bladder. J Pathol 1993; 170: 67-72.
69. Kim YW, Huh SH, Park YK et al. Expression of the c-erb-B2 and p53 protein in gallbladder carcinomas. Oncol Rep 2001; 8: 1127-1132.
70. Chaube A, Tewari M, Garbyal RS et al. Preliminary study of p53 and c-erbB-2 expression in gallbladder cancer in Indian patients manuscript id: 8962091628764582. BMC Cancer 2006; 6: 126.
71. Cabibi D, Licata A, Barresi E et al. Expression of cytokeratin 7 and 20 in pathological conditions of the bile tract. Pathol Res Pract 2003; 199: 65-70.
72. Chang HJ, Kim SW, Lee BL et al. Phenotypic alterations of mucins and cytokeratins during gallbladder carcinogenesis. Pathol Int 2004; 54: 576-584.
73. Chang YT, Hsu C, Jeng YM et al. Expression of the caudal-type homeodomain transcription factor CDX2 is related to clinical outcome in biliary tract carcinoma. J Gastroenterol Hepatol 2007; 22: 389-394.
74. Duval JV, Savas L, Banner BF. Expression of cytokeratins 7 and 20 in carcinomas of the extrahepatic biliary tract, pancreas, and gallbladder. Arch Pathol Lab Med 2000; 124: 1196-1200.
75. Harder J, Waiz O, Otto F et al. EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol 2009; 15: 4511-4517.
76. Kalekou H, Miliaras D. Cytokeratin 7 and 20 expression in gallbladder carcinoma. Pol J Pathol 2011; 62: 25-30.
77. Kaufman M, Mehrotra B, Limaye S et al. EGFR expression in gallbladder carcinoma in North America. Int J Med Sci 2008; 5: 285-291.
78. Lee CS, Pirdas A. Epidermal growth factor receptor immunoreactivity in gallbladder and extrahepatic biliary tract tumours. Pathol Res Pract 1995; 191: 1087-1091.
79. Li QL, Yang ZL, Liu JQ et al. Expression of CDX2 and hepatocyte antigen in benign and malignant lesions of gallbladder and its correlation with histopathologic type and clinical outcome. Pathol Oncol Res 2011; 17: 561-568.
80. Moon WS, Park HS, Lee H et al. Co-expression of cox-2, C-met and beta-catenin in cells forming invasive front of gallbladder cancer. Cancer Res Treat 2005; 37: 171-176.
81. Nakazawa K, Dobashi Y, Suzuki S et al. Amplification and overexpression of cerbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol 2005; 206: 356-365.
82. Ooi A, Suzuki S, Nakazawa K et al. Gene amplification of Myc and its coamplification with ERBB2 and EGFR in gallbladder adenocarcinoma. Anticancer Res 2009; 29: 19-26.
83. Sakamoto H, Mutoh H, Ido K et al. A close relationship between intestinal metaplasia and Cdx2 expression in human gallbladders with cholelithiasis. Hum Pathol 2007; 38: 66-71.
84. Sasaki M, Yamato T, Nakanuma Y et al. Expression of MUC2, MUC5AC and MUC6 apomucins in carcinoma, dysplasia and non-dysplastic epithelia of the gallbladder. Pathol Int 1999; 49: 38-44.
85. Shafizadeh N, Grenert JP, Sahai V et al. Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder. Hum Pathol 2010; 41: 485-492.
86. Wu XS, Akiyama Y, Igari T et al. Expression of homeodomain protein CDX2 in gallbladder carcinomas. J Cancer Res Clin Oncol 2005; 131: 271-278.
87. Xiong L, Yang Z, Yang L et al. Expressive levels of MUC1 and MUC5AC and their clinicopathologic significances in the benign and malignant lesions of gallbladder. J Surg Oncol 2012; 105: 97-103.
88. Yamato T, Sasaki M, Watanabe Y et al. Expression of MUC1 and MUC2 mucin core proteins and their messenger RNA in gallbladder carcinoma: an immunohistochemical and in situ hybridization study. J Pathol 1999; 188: 30-37.
89. Ghosh M, Kamma H, Kawamoto T et al. MUC1 core protein as a marker of gallbladder malignancy. Eur J Surg Oncol 2005; 31: 891-896.
90. Kim HJ, Kim SH, Chae GB et al. Increased expression of mucin 5AC mRNA and decreased expression of epidermal growth-factor receptor mRNA in gallstone patients. Tohoku J Exp Med 2008; 214: 139-144.
91. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006; 12: 5268-5272.
92. Kim YS, Gum J, Jr, Brockhausen I. Mucin glycoproteins in neoplasia. Glycoconj J 1996; 13: 693-707.
93. Reis CA, David L, Correa P et al. Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression. Cancer Res 1999; 59: 1003-1007.
94. Chuang SC, Hsi E, Lee KT. Mucin genes in gallstone disease. Clin Chim Acta 2012; 413: 1466-1471.
95. Finzi L, Barbu V, Burgel PR et al. MUC5AC, a gel-forming mucin accumulating in gallstone disease, is overproduced via an epidermal growth factor receptor pathway in the human gallbladder. Am J Pathol 2006; 169: 2031-2041.
96. Vilkin A, Nudelman I, Morgenstern S et al. Gallbladder inflammation is associated with increase in mucin expression and pigmented stone formation. Dig Dis Sci 2007; 52: 1613-1620.
97. Boonla C, Wongkham S, Sheehan J et al. Prognostic value of serum MUC5AC mucin in patients with cholangiocarcinoma. Cancer 2003; 98: 1438-1443.
98. Park S, Roh S, Kim Y et al. Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: prognostic impact. Oncol Rep 2009; 22: 649-657.
99. Natarajan S, Xu F, Gilchrist K et al. Cytokeratin is a superior marker for detection of micrometastatic biliary tract carcinoma. J Surg Res 2005; 125: 9-15.
100. Yokoyama N, Shirai Y, Hatakeyama K. Immunohistochemical detection of lymph node micrometastases from gallbladder carcinoma using monoclonal anticytokeratin antibody. Cancer 1999; 85: 1465-1469.
101. Tajima Y, Tomioka T, Ikematsu Y et al. Immunohistochemical demonstration of cytokeratin is useful for detecting micrometastatic foci from gallbladder carcinoma in regional lymph nodes. Jpn J Clin Oncol 1999; 29: 425-428.
102. Kim HS, Kim GY, Lim SJ et al. Reduced expression of Raf-1 kinase inhibitory protein is a significant prognostic marker in patients with gallbladder carcinoma. Hum Pathol 2010; 41: 1609-1616.
103. Li J, Wu T, Lu J et al. Immunohistochemical evidence of the prognostic value of hedgehog pathway components in primary gallbladder carcinoma. Surg Today 2012; 42: 770-775.
104. Li Q, Yang Z. Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations. J Exp Clin Cancer Res 2009; 28: 65.
105. Liu DC, Yang ZL. Overexpression of EZH2 and loss of expression of PTEN is associated with invasion, metastasis, and poor progression of gallbladder adenocarcinoma. Pathol Res Pract 2011; 207: 472-478.
106. Liu DC, Yang ZL, Jiang S. Identification of PEG10 and TSG101 as carcinogenesis, progression, and poor-prognosis related biomarkers for gallbladder adenocarcinoma. Pathol Oncol Res 2011; 17: 859-866.
107. Wang W, Yang ZL, Liu JQ et al. Identification of CD146 expression, angiogenesis, and lymphangiogenesis as progression, metastasis, and poor-prognosis related markers for gallbladder adenocarcinoma. Tumour Biol 2012; 33: 173-182.
108. Yang L, Lan S, Liu J et al. Expression of MK-1 and RegIV and its clinicopathological significances in the benign and malignant lesions of gallbladder. Diagn Pathol 2011; 6: 100.
109. Yang Z, Xiong L, Huang S et al. Expression of VHL and HIF-1alpha and their clinicopathologic significance in benign and malignant lesions of the gallbladder. Appl Immunohistochem Mol Morphol 2011; 19: 534-539.
110. Zou Q, Xiong L, Yang Z et al. Expression levels of HMGA2 and CD9 and its clinicopathological significances in the benign and malignant lesions of the gallbladder. World J Surg Oncol 2012; 10: 92.
111. Roa I, de Aretxabala X, Lantadilla S et al. ERCC1 (excision repair crosscomplementing 1) expression in pT2 gallbladder cancer is a prognostic factor. Histol Histopathol 2011; 26: 37-43.
112. Hobbs SS, Goettel JA, Liang D et al. TNF transactivation of EGFR stimulates cytoprotective COX-2 expression in gastrointestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2011; 301: G220-G229.
113. Gray T, Nettesheim P, Loftin C et al. Interleukin-1beta-induced mucin production in human airway epithelium is mediated by cyclooxygenase-2, prostaglandin E2 receptors, and cyclic AMP-protein kinase A signaling. Mol Pharmacol 2004; 66: 337-346.
114. Nadel JA. Role of epidermal growth factor receptor activation in regulating mucin synthesis. Respir Res 2001; 2: 85-89.
115. Vishnoi M, Pandey SN, Choudhuri G et al. IL-1 gene polymorphisms and genetic susceptibility of gallbladder cancer in a north Indian population. Cancer Genet Cytogenet 2008; 186: 63-68.
116. Sinicrope FA, Lemoine M, Xi L et al. Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. Gastroenterology 1999; 117: 350-358.
117. Karnes WE, Jr., Shattuck-Brandt R, Burgart LJ et al. Reduced COX-2 protein in colorectal cancer with defective mismatch repair. Cancer Res 1998; 58: 5473-5477.
118. Barreto SG, Haga H, Shukla PJ. Hormones and gallbladder cancer in women. Indian J Gastroenterol 2009; 28: 126-130.
119. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
120. Yap TA, Gerlinger M, Futreal PA et al. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 2012; 4: 127ps110.
121. Watson P, Vasen HF, Mecklin JP et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 2008; 123: 444-449.
122. Kim ET, Namgung H, Shin HD et al. Oncologic manifestations of neurofibromatosis type 1 in Korea. J Korean Surg Soc 2012; 82: 205-210.
123. Lowenfels AB, Maisonneuve P, Boyle P et al. Epidemiology of gallbladder cancer. Hepatogastroenterology 1999; 46: 1529-1532.
124. Hemminki K, Li X. Familial liver and gall bladder cancer: a nationwide epidemiological study from Sweden. Gut 2003; 52: 592-596.
125. Subbiah IM, Subbiah V, Tsimberidou AM et al. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget 2013; 4: 156-165.
126. Subbiah IM, Subbiah V, Tsimberidou AM et al. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget 2013; 4: 153-162.
127. Caldow Pilgrim CH, Groeschl RT, Quebbeman EJ et al. Recent advances in systemic therapies and radiotherapy for gallbladder cancer. Surg Oncol 2013; 22: 61-67.